LRMR

Larimar Therapeutics Inc

Add to Watchlist

Advanced Chart

3.880

-0.01(-0.257%)1D

Line

Candle

YTD

High

4.0596

Open

3.860

VWAP

3.86

Vol

1.06M

Mkt Cap

332.09M

Low

3.760

Amount

4.07M

EV/EBITDA(TTM)

Total Shares

63.80M

194.42M

EV/OCF(TTM)

P/S(TTM)

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-0.423

+76.26%

-0.421

-6.5%

-0.422

-8.15%

Estimates Revision

The market is revising No Change the revenue expectations for Larimar Therapeutics, Inc. (LRMR) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 17.22%.

EPS Estimates for FY2025

Revise Downward

-11.31%

In Past 3 Month

Stock Price

Go Up

+17.22%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast LRMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LRMR is 17.25 USD with a low forecast of 7.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

0 Hold

0 Sell

Strong Buy

Current: 3.880

Low

7.00

Averages

17.25

High

26.00

Current: 3.880

Low

7.00

Averages

17.25

High

26.00

Baird

Joel Beatty

Outperform

downgrade

$10 -> $7

2025-09-30

Reason

Baird

Joel Beatty

Price Target

$10 -> $7

2025-09-30

downgrade

Outperform

Reason

Baird analyst Joel Beatty lowered the firm's price target on Larimar Therapeutics to $7 from $10 and keeps an Outperform rating on the shares. The firm updated its model to reflect increased safety and regulatory risk following the company's Nomla update.

Citizens JMP

Jonathan Wolleben

Outperform

downgrade

$22 -> $18

2025-08-15

Reason

Citizens JMP

Jonathan Wolleben

Price Target

$22 -> $18

2025-08-15

downgrade

Outperform

Reason

Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on Larimar Therapeutics to $18 from $22 and keeps an Outperform rating on the shares. Larimar will have new open-label data for nomlabofusp in September, which should provide more confidence in the Friedreich's ataxia candidate, the analyst tells investors in a research note.

Citi

Buy

maintain

$14

2025-06-24

Reason

Citi

Price Target

$14

2025-06-24

maintain

Buy

Reason

Citi views yesterday's selloff in shares of Larimar Therapeutics as a buying opportunity. Larimar announced that the FDA recommended the safety database for nomlabofusp include at least 30 patients with continuous exposure for six months, including a subset of at least 10 patients for one year, with the large majority receiving the 50mg dose, the analyst tells investors in a research note. The firm says that with full FDA alignment in hand, Larimar has a clear path to application submission, which is now guided for Q2 of 2026 versus the second half of 2025 previously, to allow for additional time to collect one year of safety follow-up for patients. Citi keeps a Buy rating on the shares with a $14 price target.

Wedbush

Outperform

NULL

downgrade

$17 -> $15

2025-06-24

Reason

Wedbush

Price Target

$17 -> $15

2025-06-24

downgrade

Outperform

NULL

Reason

HC Wainwright & Co.

Edward White

Strong Buy

Maintains

$15 → $16

2025-03-25

Reason

HC Wainwright & Co.

Edward White

Price Target

$15 → $16

2025-03-25

Maintains

Strong Buy

Reason

Baird

Joel Beatty

Buy

Maintains

$13 → $10

2025-03-25

Reason

Baird

Joel Beatty

Price Target

$13 → $10

2025-03-25

Maintains

Buy

Reason

Baird lowered the firm's price target on Larimar Therapeutics to $10 from $13 and keeps an Outperform rating on the shares. Th efirm updated its model following Q4 results which showed the FDA is open to Skin FXN as a surogate endpoint with a BLA planned by year-end 2025.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Larimar Therapeutics Inc (LRMR.O) is -2.40, compared to its 5-year average forward P/E of -3.77. For a more detailed relative valuation and DCF analysis to assess Larimar Therapeutics Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.77

Current PE

-2.40

Overvalued PE

-1.90

Undervalued PE

-5.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.21

Current EV/EBITDA

-1.48

Overvalued EV/EBITDA

0.33

Undervalued EV/EBITDA

-2.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.02

Current PS

3.89

Overvalued PS

0.28

Undervalued PS

-0.25